| Literature DB >> 32720874 |
Ferdinando Petrazzuoli1, Shlomo Vinker2, Sebastian Palmqvist3, Patrik Midlöv1, Jan De Lepeleire4, Alessandro Pirani5, Thomas Frese6, Nicola Buono7, Jette Ahrensberg8, Radost Asenova9, Quintí Foguet Boreu10, Gülsen Ceyhun Peker11, Claire Collins12, Miro Hanževački13, Kathryn Hoffmann14, Claudia Iftode15, Tuomas H Koskela16, Donata Kurpas17, Jean Yves Le Reste18, Bjørn Lichtwarck19, Davorina Petek20, Diego Schrans21, Jean Karl Soler22, Sven Streit23, Athina Tatsioni24, Péter Torzsa25, Pemra C Unalan26, Harm van Marwijk27, Hans Thulesius1,28.
Abstract
OBJECTIVE: To explore dementia management from a primary care physician perspective.Entities:
Keywords: Dementia; drug prescription; elderly people; grounded theory; primary care; unburdening
Year: 2020 PMID: 32720874 PMCID: PMC7470166 DOI: 10.1080/02813432.2020.1794166
Source DB: PubMed Journal: Scand J Prim Health Care ISSN: 0281-3432 Impact factor: 2.581
The basic social process of Unburdening Dementia.*
| Unburdening Dementia - a two-step Basic Social Process | ||
| BASIC SOCIAL PROCESS STAGE: | ||
| APPLIED TO DEMENTIA CARE : | Cognitive, mental and social | |
| CASE STORY ILLUSTRATION: | Consultation together: spouse/child report memory loss. Physician notices lack of collaboration during consultation. Assessment with Mini Mental State Examination. Physician diagnoses the patient with dementia. | |
The table illustrates the basic social process of Unburdening Dementia that emerged to explain the action in the data provided by primary care physicians across EGPRN countries. *Basic social processes are grounded theory core variables that are ‘processural’ meaning that they have two or more clear emergent stages [13,14]. Descriptive incidents of community health and home help services (such as nursing home care and dementia services) appeared in more than half of the case stories as indicators of a property of Burden Relief.
Demographics, dementia prevalence, grades of dementia drug prescribing permissiveness in the participating countries and share of dementia drugs prescribed in the case stories per region.
| Country | Population million people | Population 65 years old or over (%) | Dementia prevalence (%) | Primary care physician allowed to prescribe dementia drugs? | Number of case stories (% of total) | Proportion of typical dementia drug treatment per case per region |
|---|---|---|---|---|---|---|
| Denmark | 5.8 | 18.2 | 1.5 | PARTIAL | 3 (2) | |
| Finland | 5.5 | 19.4 | 1.7 | NO | 4 (3) | |
| Norway | 5.2 | 15.9 | 1.6 | YES | 6 (4) | |
| Sweden | 9.7 | 19.4 | 1.8 | YES | 8 (5) | |
| North Countries, total | 21 | 57% | ||||
| Austria | 8.6 | 18.3 | 1.7 | NO | 3 (2) | |
| Belgium | 11.3 | 17.8 | 1.8 | PARTIAL | 2 (1) | |
| France | 66.4 | 18.0 | 1.8 | PARTIAL | 5 (3) | |
| Germany | 81.2 | 20.8 | 1.9 | YES | 5 (3) | |
| Ireland | 4.6 | 12.6 | 1.1 | YES | 35 (23) | |
| Switzerland | 8.2 | 17.6 | 1.7 | YES | 5 (3) | |
| The Netherlands | 16.9 | 17.3 | 1.5 | PARTIAL | 5 (3) | |
| West Countries, total | 60 | 67% | ||||
| Bulgaria | 7.2 | 19.6 | 1.5 | NO | 5 (3) | |
| Croatia | 4.2 | 18.4 | 1.5 | NO | 3 (2) | |
| Hungary | 9.8 | 17.5 | 1.5 | NO | 3 (2) | |
| Poland | 38.0 | 14.9 | 1.3 | NO | 20 (13) | |
| Romania | 19.9 | 16.5 | 1.3 | NO | 10 (6) | |
| Slovenia | 2.1 | 17.5 | 1.6 | PARTIAL | 4 (3) | |
| East Countries, total | 45 | 40% | ||||
| Greece | 10.8 | 20.5 | 1.8 | NO | 4 (3) | |
| Israel | 8.5 | 10.3 | 1.1 | NO | 7 (5) | |
| Italy | 60.6 | 21.4 | 2.1 | NO | 8 (5) | |
| Malta | 0.4 | 17.9 | 1.3 | NO | 1 (1) | |
| Spain | 46.4 | 18.1 | 1.8 | NO | 6 (4) | |
| Turkey | 77.7 | 7.7 | 0.4 | NO | 3 (2) | |
| Mediterranean Countries, total | 29 | 66% | ||||
| Total | 155 | 57% |
Legend: Demography, dementia prevalence, prescription rules for primary care physicians, dementia cases stories and proportion of typical dementia drug treatment from 25 countries in the EGPRN. Data on dementia prevalence by Prince et al. 2013 and on dementia drug prescribing rules by the Alzheimer Europe Association, 2012.
Figure 1. Importance of predictors of primary care physician involvement in dementia work-up and treatment. Degree of involvement is dichotomised into two groups by a two-step cluster analysis.Cluster analysis is an exploratory method to identify structures within the data such as homogenous groups of cases if grouping is not previously known. ‘Exploratory’ means that it makes no distinction between dependent and independent variables. We used the SPSS Version 22 two-step cluster analysis. The most important predicting variables to allocate the informants in the two groups were ‘permissiveness to prescribe dementia drugs’ (Predictor importance PI = 1) and ‘country’ (PI = 0.61). All the other variables had a PI of < 0.02. Permissiveness: official permissiveness to prescribe typical dementia drug reimbursed by the local health care system. Country: country of the case and his/her primary care physician. Appropriate treatment: appropriate treatment according to the dementia guidelines and the label indication. Age: age of the case in years. Gender: gender of the case. MMSE: mini mental state examination. Number of words in case: word count in the case description.
Dementia drug treatment stratified by diagnostic group.
| Dementia Drug | Total number of patients | ||
|---|---|---|---|
| Diagnosis | No regular dementia drug | Regular dementia drug (acetylcholinesterase inhibitors/memantine) | |
| No diagnostic information available | 4 | 0 | 4 |
| Alzheimer’s Disease/Major Neurocognitive Disorder (*) | 9 | 31 | 40 |
| Vascular Dementia /Major Neurocognitive Disorder (†) | 12 | 4 | 16 |
| Major Neurocognitive Disorder unspecified (β) | 19 | 31 | 50 |
| Normal Pressure Hydrocephalus | 1 | 0 | 1 |
| Mild Neurocognitive Disorder unspecified | 5 | 0 | 5 |
| Major Neurocognitive Disorders, mixed aetiologies | 10 | 22 | 32 |
| Fronto-Temporal Dementia (β) | 3 | 1 | 4 |
| Dementia of Lewy Body | 1 | 0 | 1 |
| Alzheimer’s Disease/ Mild Neurocognitive Disorders | 2 | 0 | 2 |
| Total | 66 | 89 | 155 |
Legend: Memantine and acetylcholinesterase inhibitors were considered appropriately used if they were prescribed to patients with Alzheimer’s disease (AD), mixed dementia (if AD was considered one of the components), dementia with Lewy bodies or Parkinson’s disease dementia. The indication for the treatment was considered correct regardless of dementia stage (i.e. memantine was not restricted to moderate to severe AD and acetylcholinesterase inhibitors was not restricted to mild to moderate AD) [21].
(*) = appropriate prescription of acetylcholinesterase inhibitors/memantine.
(β) = questionable prescription of acetylcholinesterase inhibitors/memantine.
(†) = inappropriate prescription of acetylcholinesterase inhibitors/memantine.